NEUROCRINE BIOSCIENCES
Neurocrine Biosciences engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company develops drugs for endometriosis, anxiety, depression, pain, diabetes, irritable bowel syndrome, insomnia, and other neurological and endocrine related diseases and disorders. Its products in clinical development comprise Elagolix, a Phase II product for Endometriosis; CRF1 Antagonist, a phase II product for mood... disorders; CRF2 Peptide Agonist, a phase II drug for Cardiovascular related diseases; CRF1 Antagonist, a Phase I product for treating Mood Disorders and Irritable Bowel Syndrome; and Elagolix, a Phase I product for treating Benign Prostatic Hyperplasia and Uterine Fibroids. The company's research programs include Vesicular Monoamine Transporter 2 Inhibitor for movement disorders and schizophrenia; Glucose Dependent Insulin Secretagogues for type II diabetes; Antiepileptic drugs for epilepsy and bipolar disorder; and GnRH Antagonists for hormone dependent diseases and oncology. It has strategic alliances with GlaxoSmithKline to develop and commercialize CRF antagonists for psychiatric, neurological, and gastrointestinal diseases; and Dainippon Sumitomo Pharma Co. Ltd. to develop and commercialize indiplon in Japan. Neurocrine Biosciences, Inc. was founded in 1992 and is based in San Diego, California.
NEUROCRINE BIOSCIENCES
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
1992-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.neurocrine.com
Total Employee:
251+
Status:
Active
Contact:
(858) 617-7600
Email Addresses:
[email protected]
Total Funding:
10 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics
Similar Organizations
Idera Pharmaceuticals
Idera Pharmaceuticals is engaged in the discovery and development of novel synthetic DNA and RNA-based drug candidates.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2022-08-30 | Diurnal Group | Diurnal Group acquired by Neurocrine Biosciences | 48.3 M GBP |
| 1998-03-03 | Northwest Neurologic | Northwest Neurologic acquired by Neurocrine Biosciences | N/A |
Investors List
Venrock
Venrock investment in Post-IPO Equity - Neurocrine Biosciences
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2019-12-02 | Xenon Pharmaceuticals | Neurocrine Biosciences investment in Post-IPO Equity - Xenon Pharmaceuticals | 30 M USD |
Key Employee Changes
| Date | New article |
|---|---|
| 2021-11-30 | Neurocrine Biosciences Appoints Jude Onyia, Ph.D., as Chief Scientific Officer |
Official Site Inspections
http://www.neurocrine.com Semrush global rank: 1.61 M Semrush visits lastest month: 15.68 K
- Host name: 20.119.8.58
- IP address: 20.119.8.58
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
